SCARLETRED Holding GmbH was honored to be invited to the official presentation of the new clinical research hub at the Medical University of Vienna (MedUni Wien) Campus. With this addition, clinical research, education, and collaboration are set to be bound stronger than ever.

A major investment in the future of medicine

The presentation introduced the two major clinical research hub extensions of MedUni Wien – currently in construction:

The Center for Translational Medicine (CTM) and the Eric Kandel Institute – Center for Precision Medicine (CPM). SCARLETRED representatives were welcomed by Prof. Dr. Markus Zeitlinger, Head of Department of Clinical Pharmacology, and Agnes Bugajska-Schretter.

SCARLETRED & MedUni Wien: Proven track record in joint research

Over the past years, SCARLETRED has collaborated closely with MedUni Wien and Prof. Dr. Markus Zeitlinger on several impactful research initiatives.

These include the diagnostic accuracy study on the sensitivity and specificity of SARS-CoV-2 rapid antigen detection tests using oral, anterior nasal and nasopharyngeal swabs during Covid-19 pandemic where Scarletred®Vision technology was integrated and used for standardized test documentation and signal quantification.

The result of the study was published in Microbiology Spectrum - download the full paper here:
‍Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Detection Tests Using Oral, Anterior Nasal, and Nasopharyngeal Swabs: a Diagnostic Accuracy Study

ARORA®AI-powered ISR assessment with Prof. Dr. Markus Zeitlinger

Another significant joint clinical trial focused on “Randomized, Double-blind, Phase I Pharmacokinetic Study of Subcutaneous Recombinant Human Superoxide Dismutase (rhSOD) in Healthy Volunteers” with SCARLETRED as the sponsor of the study.

MedUni Vienna as a study center investigated a recombinant human superoxide dismutase (rhSOD) as a treatment for severe hyper-inflammatory diseases linked to significantly increased oxidative stress, such as observed in severe forms of Covid-19 or Influenza.

In this Phase Ib clinical trial in healthy volunteers, the investigational drug was administered subcutaneously and demonstrated a favorable safety and tolerability profile. The joint research was led by Prof. Dr. Markus Zeitlinger as principal investigator, with Scarletred®Vision integrated to enable standardized skin imaging, electronic clinical outcome assessment (eCOA), and electronic patient-reported outcomes (ePRO).

Moreover, SCARLETRED’s agentic AI, ARORA®, was retrospectively deployed for the first time on the image dataset to detect and quantify the intensity of documented injection site reactions (ISRs). This study achieved two breakthroughs: a first-in-human validation and the first use of AI in such a clinical setting.

The result of the study was published in Clinical Pharmacokinetics - download the full paper here:
‍Randomized, Double‐Blind, Phase I Pharmacokinetic Study of Subcutaneous Recombinant Human Superoxide Dismutase (rhSOD) in Healthy Volunteers

New Research Hub: 850 million euros for interdisciplinary improvement

Both new research centers are planned to be opened on October 1st, 2026, at the campus of MedUni Wien. The construction embodies a key component of a large-scale campus expansion designed to strengthen Austria’s position in cutting-edge medical research.  

The initiative is part of an extensive investment program of approximately 850 million euros, aimed at creating a highly integrated environment for research, clinical care, and education.

The new campus infrastructure brings together disciplines such as translational medicine, bioinformatics, and early-phase clinical trials in one single location. By fostering tight interaction between scientists, clinicians, and industry partners, the centers are expected to accelerate the translation of scientific discoveries into clinical applications and foster data-driven medicine.

The next generation of clinical studies

The new dedicated research environment is expected to significantly enhance capacities for clinical studies and interdisciplinary collaboration.  

SCARLETRED sees strong potential in fostering its collaborations with MedUni Wien within its new ecosystem. By contributing with expertise in AI-powered digital biomarkers, standardized skin assessment, dataset management and documentation, SCARLETRED aims to support the next generation of clinical studies and help drive data-driven innovation in translational and precision medicine.

With shared ambitions to bridge technology and clinical science, SCARLETRED and MedUni Wien continue to build a shared vision focused on advancing research and future-oriented healthcare.

Further Information on the New Clinical Research Hub at MedUni Wien

Center for Translational Medicine (CTM)

The Center for Translational Medicine connects basic science with clinical practice, fostering the collaborative development of new research and clinical trial projects. The center shall therefore offer a seamless pathway from experimental laboratory testing to Phase I/II clinical research – all within one single building.  

This measure shall accelerate the transfer of scientific findings into tangible improvements for patients.

Find out more here.

Eric Kandel Institute - Center for Precision Medicine (CPM)

The Eric Kandel Institute - Center for Precision Medicine at the Medical University of Vienna, is planned to open in 2027. Named after the Vienna-born Nobel laureate Eric Kandel, the institute will focus on the research and development of personalized and digital medicine – two key future fields in medical science.

The goal is to develop innovative prevention, diagnostic, and therapeutic concepts and to consolidate key technologies in precision medicine at a single location. The institute is a strategic key project for strengthening the international visibility of Vienna as a center of high-quality, future-oriented healthcare.

Find out more here.

‍

‍